Evidence map›Paper›PMID 34359650›Full record

ArticleCancers2021

Targeted Liposomal Chemotherapies to Treat Triple-Negative Breast Cancer.

Yingnan Si, Ya Zhang, Hanh Giai Ngo, Jia-Shiung Guan, Kai Chen, Qing Wang, Ajeet Pal Singh, Yuanxin Xu, Lufang Zhou, Eddy S Yang and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.4field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. A Nanorobotics-Based Approach of Breast Cancer in the Nanotechnology Era.International journal of molecular sciences · 2024
    Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Yingnan SiDepartment of Biomedical Engineering, University of Alabama at Birmingham, 1825 University Blvd, Birmingham, AL 35294, USA.
Ya ZhangDepartment of Biomedical Engineering, University of Alabama at Birmingham, 1825 University Blvd, Birmingham, AL 35294, USA.
Hanh Giai NgoDepartment of Biomedical Engineering, University of Alabama at Birmingham, 1825 University Blvd, Birmingham, AL 35294, USA.
Jia-Shiung GuanDepartment of Medicine, University of Alabama at Birmingham, 703 19th Street South, Birmingham, AL 35294, USA.
Kai ChenDepartment of Biomedical Engineering, University of Alabama at Birmingham, 1825 University Blvd, Birmingham, AL 35294, USA.
Qing WangDepartment of Biomedical Engineering, University of Alabama at Birmingham, 1825 University Blvd, Birmingham, AL 35294, USA.
Ajeet Pal SinghDepartment of Biomedical Engineering, University of Alabama at Birmingham, 1825 University Blvd, Birmingham, AL 35294, USA.
Yuanxin XuDepartment of Medicine, University of Alabama at Birmingham, 703 19th Street South, Birmingham, AL 35294, USA.
Lufang ZhouDepartment of Biomedical Engineering, University of Alabama at Birmingham, 1825 University Blvd, Birmingham, AL 35294, USA.ORCID 0000-0002-1321-8442
Eddy S YangDepartment of Radiation Oncology, University of Alabama at Birmingham, 1808 7th Avenue South, Birmingham, AL 35294, USA.ORCID 0000-0002-6450-2638
Xiaoguang Margaret LiuDepartment of Biomedical Engineering, University of Alabama at Birmingham, 1825 University Blvd, Birmingham, AL 35294, USA.ORCID 0000-0002-4617-9750
University of Alabama at Birmingham · US

Funding

Synergistic Targeted Therapy of Antibody-Drug Conjugates for Triple-Negative Breast CancerR01CA238273 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LIU, RUNHUA RUNA, LIU, XIAOGUANG MARGARET · 2020 to 2025
$2.4M
Identifying a New Biological Target for Breast Cancer Therapy That Contributes to Disparities for African-American WomenR01CA242917 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LIU, RUNHUA RUNA, LIU, XIAOGUANG MARGARET · 2020 to 2024
$1.7M
NIH HHS 1R01CA238273-01A1; 1R01CA242917-01A1
6 · The paper itself

Abstract

Triple-negative breast cancers (TNBCs) are highly aggressive and recurrent. Standard cytotoxic chemotherapies are currently the main treatment options, but their clinical efficacies are limited and patients usually suffer from severe side effects. The goal of this study was to develop and evaluate targeted liposomes-delivered combined chemotherapies to treat TNBCs. Specifically, the IC

Indexed as

combined chemotherapiestargeted liposomestriple-negative breast cancer

Identifiers

PMID34359650
PMCPMC8345094
OpenAlexW3186368334

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.